Cancer is the world’s second greatest cause of mortality, after heart disease. However, the likelihood of dying from cancer has decreased in recent decades, largely to advancements in treatment, diagnosis and prevention. Doctors at the University of California, Los Angeles are working on this. Immunotherapy has revolutionized cancer treatment by using the body’s immune system to attack cancer cells and halt tumor growth. However, these treatments frequently need to be adjusted to each individual patient, slowing down the treatment process and increasing the drug’s cost. To overcome these obstacles, researchers at the University of California, Los Angeles, have created a novel clinically controlled method for producing stronger immune cells. You may also learn about how L.A. Care health insurance works. Find out more at i-los-angeles.
How did the concept of immunotherapy emerge?
The foundation of immunotherapy as a cancer treatment is the use of the human immune system as a whole, including its cells, molecules and interaction principles, to combat cancer. Immunotherapy, like chemotherapy and radiation, has a lengthy research history. Immunotherapy arose from the work of pioneering scientists and, as with many scientific breakthroughs, by coincidence. The first sparks of research into the immune system and its operation began in the late nineteenth century, when a young girl in the United States developed a rare condition. In the summer of 1890, 17-year-old Bessie Dashiell suffered from persistent pain caused by an arm wound. When the wound on her arm was not healing, but only getting worse, Dashiell came to Dr. William Coley. During examination, the surgeon discovered a small amount of pus and tissue that was abnormally hard and more grayish than usual. A tissue biopsy determined that it was a sarcoma. At thre time, amputation was the best treatment option available. In November 1890, two days after the biopsy results, Coley amputated the girl’s right arm below the elbow. However, following the amputation, the disease rapidly spread and tumors appeared all over the body. Eventually, the girl died. The doctor was struck by this account, so he began the first research. So, thanks to his curiosity, he was able to discover a way to manipulate the immune system to treat diseases. He conducted experiments with vaccines to treat patients. As a result, the experiment was successful. Coley developed this therapy at a time when radiation was first introduced as a cancer treatment option.
How does immunotherapy work?
Immunotherapy is an advanced treatment that enhances cellular immunity rather than employing chemotherapy or radiation, which have non-specific targets and harmful effects on normal cells. Immune checkpoint inhibitors and T-cell-based immunotherapy have previously been proven effective against solid malignancies and leukemia. Tumor cells that elude immune monitoring are a significant barrier to achieving an effective immune response in cancer patients. In recent years, significant progress has been made in a variety of innate and adaptive immune checkpoints that play a crucial role in preventing oncogenesis.
Immunotherapy can efficiently eliminate cancer cells while causing minimal side effects. Additionaly, a number of planned actions are also taken to ensure that antitumor cells have immunity. Dendritic cells, for example, detect the release of neoantigens from malignant tumors in their early stages. The second stage is known as the processing stage, in which pro-inflammatory cytokines and molecules are released, activating T cells. Activated T cells infiltrate and destroy cancer cells. After cancer cells are eliminated, additional tumor-bound proteins are released, increasing the effectiveness of successive antitumor immunological cycles.
What makes iNKT cells unique?
Doctors believe that invariant natural killer T cells are unique immune cells because they are stronger and faster than normal T cells and may attack tumors with various weapons. Using iNKT cells for cancer immunotherapy is advantageous because they eliminate the risk of graft-versus-host disease. This is a condition in which transplanted cells attack the recipient’s body, which is why the majority of cellular immunotherapy should be personalized to each individual patient.
Recognizing the existence of inflammatory infiltrates in solid tumors and knowing what causes tumor inflammation has led to the application of immunotherapy. After all, the immune system has the ability to efficiently eradicate tumors. This has resulted in intensive research and development on cancer immunotherapy.
Research at the University of California
Researchers at the University of California are working closely with the UCLA Health Jonsson Comprehensive Cancer Center. Doctors are working together to develop new treatments based on stem cells and test them in clinical trials. For the most part, they are attempting to learn more about the qualities of cancer and find novel ways to exploit the weaknesses of these cells. Several studies aim to improve current and future immunotherapy methods by exploring novel strategies to make them more effective, safe and affordable. Doctors are developing a genetically engineered platform that generates adaptable, ready-made CAR-T cells, making T-cell immunotherapy more accessible for treatment. They are also working on an injectable, adapted cancer vaccination booster to treat and prevent tumor recurrence.
In 2021, a team of researchers at the University of California reported on a method of producing a large number of iNKT cells from blood stem cells. They created a technology that can generate a large number of iNKT cells from blood stem cells. This advancement removes earlier obstacles, bringing cancer patients closer to immunotherapy. From 15 donor cord blood samples, the researchers extracted blood stem cells capable of self-replication and the production of various blood and immune cells. They then genetically altered each of these cells to produce valuable iNKT cells, estimating that a single cord blood donation may provide 1,000 to 10,000 doses of therapy. The scientists then administered iNKT cells chimeric antigen receptors, which are molecules that enable immune cells to recognize and kill specific types of cancer. They target seven types of cancer, including both blood cancer and solid tumors.
The UCLA research center is located two miles from the Westwood campus in a former 700,000-square-foot shopping center. It is home to the California Institute for Immunology and Immunotherapy at the University of California, Los Angeles, as well as the University of California’s Center for Quantum Science and Engineering. Additionally, the Institute for Immunology and Immunotherapy is supported by a group of founding philanthropists led by Meyer Luskin, Dr. Gary Michelson, Dr. Eric Esrailian, Dr. Arie Belldegrun, Sean Parker and Michael Milken.